Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. by Chew, W et al.
Vol.:(0123456789) 
Medical Oncology (2018) 35:138 
https://doi.org/10.1007/s12032-018-1192-6
SHORT COMMUNICATION
Clinical Characteristics and efficacy of chemotherapy in sclerosing 
epithelioid fibrosarcoma
Winston Chew1 · Charlotte Benson1 · Khin Thway1,2 · Andrew Hayes1,3 · Aisha Miah1,3 · Shane Zaidi1 · Alex T. J. Lee1,2 · 
Christina Messiou1,3 · Cyril Fisher1,2 · Winette T. van der Graaf1,4 · Robin L. Jones1,4
Received: 11 June 2018 / Accepted: 10 August 2018 / Published online: 5 September 2018 
© The Author(s) 2018
Abstract
Background Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggres-
sive tumour; however, to our knowledge there are no published reports regarding the efficacy of chemotherapy in SEF. 
Therefore, the aim of this study was to document the outcome of a series of patients with SEF treated at a single referral 
centre with reference to systemic therapy.
Methods A retrospective search of a prospectively maintained database was performed to identify all patients diagnosed 
with SEF between 1990 and 2017. The diagnosis was confirmed in each case by a dedicated soft tissue sarcoma pathologist. 
We analysed those with recurrent disease and the effect of systemic chemotherapy in the metastatic setting.
Results Thirteen patients were identified, median overall survival from diagnosis and metastasis were 47.3 (95% CI 25.0–
131.9) and 16.3 (95% CI 5.3–20.6) months, respectively. In total, 12 (92.3%) patients developed metastatic disease of which 
10 died of disease, 1 was lost to follow-up and 1 had recently commenced palliative treatment. Among the 10 patients with 
metastatic disease, 7 received palliative chemotherapy. Palliative chemotherapy resulted in partial response in 1 patient, sta-
ble disease in 3 patients and progressive disease in 3 patients. Median time to disease progression was 2.7 (95% CI 1.2–4.4) 
months. Two of 13 patients were treated with adjuvant chemotherapy, receiving 6 cycles of liposomal doxorubicin and 1 
cycle of doxorubicin, respectively, with a metastasis-free survival of 28.2 and 7.1 months, respectively.
Conclusion SEF is an aggressive sarcoma subtype with a poor outcome and with limited responsiveness to conventional 
chemotherapy. Patients with this subtype should be considered for participation in clinical trials with novel agents. Further 
investigation into the biology of this rare disease is required to improve outcomes.
Keywords Sclerosing epithelioid fibrosarcoma · Treatment · Prognosis · Chemotherapy
Introduction
Sclerosing epithelioid fibrosarcoma (SEF) is a rare and 
aggressive sarcoma subtype with little more than a hundred 
cases described in the literature. SEF was first described by 
Meis-Kindblom et al. in 1995 [1] as a proliferation of neo-
plastic oval or round cells arranged in cords or a nest-like 
distribution against a collagen background with prominent 
features of sclerosis. This variant of fibrosarcoma has a typi-
cally low-grade histological appearance with a low mitotic 
count and lacks the presence of necrosis. When present, 
the carcinoma-like infiltrating growth pattern in SEF dif-
ferentiates this malignancy from other epithelioid tumours. 
Alternatively, when these features are absent, the deceptively 
bland morphology compounds the difficulty in distinguish-
ing fibrosarcoma from other fibrous growths (i.e. desmoid 
tumours, nodular fasciitis). SEF typically originates in the 
lower extremities with a high propensity for local recurrence 
after surgical resection and eventual metastasis to the lungs 
and bones [1]. The rarity of this disease [2] and the chal-
lenges of establishing a positive histological diagnosis have 
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resulted in limitations to clinical and biological understand-
ing of SEF.
However, there have been improvements in identifying 
SEF and distinguishing it from other types of fibrosarcoma. 
Doyle et al. reported that the immunohistochemical expres-
sion of MUC4 was seen in 78% of SEF and when coupled 
together with FUS gene, rearrangement was a sensitive and 
relatively specific marker for SEF [3] while Arbajian et al. 
found that EWSR1-CREB3L1 gene fusions were distinguish-
ing features between SEF and the morphologically similar 
low-grade fibromyxoid sarcoma [4]. Furthermore, attempts 
have been made to characterise SEF originating from spe-
cific sites of the body, Leona et al. recently described a series 
of primary SEFs of bone [5].
As the diagnosis of SEF becomes better defined, the ques-
tion of optimal therapeutic strategy can be more confidently 
addressed. However, reports of systemic treatment outcomes 
have been limited to a handful of case reports where patients 
were treated with either single agent doxorubicin or in com-
bination with ifosfamide, methotrexate, or cisplatin [6]. The 
aim of our study was to record the outcome of a consecutive 
series of patients with SEF treated at a single referral centre 
with particular reference to systemic therapy.
Methods
A retrospective search of a prospectively maintained insti-
tutional database was performed to identify patients with 
SEF at the Royal Marsden Hospital. All data collection and 
usage for this study were approved by the hospital review 
board. Our study identified patients who were diagnosed 
with SEF between 1990 and 2017, including those with a 
retrospective diagnosis based on a review of histology fol-
lowing the first description of SEF in 1995. Histology slides 
of each case of SEF diagnosis were reviewed by a dedicated 
soft tissue sarcoma pathologist (CF, KT) for the purpose of 
this study. Tumour grade was assessed using the FNCLCC 
system while tumour size was taken from the largest dimen-
sion recorded in the pathological report. Associated base-
line clinicopathological data, treatment details and patient 
outcome data were collected by retrospective notes review. 
All patients were treated in a specialist sarcoma oncology 
clinic with treatment decisions based on multi-disciplinary 
team discussion and the discretion of the treating physician. 
Overall survival and time to metastasis were defined as the 
time of SEF diagnosis to death or metastasis, where SEF 
diagnosis was defined as the time at which that patient pre-
sented with symptoms caused by SEF. Additionally, sys-
temic chemotherapy response was evaluated using RECIST 
1.1, where time to disease progression was defined as time 
from 1st dose of chemotherapy to time of radiological dis-
ease progression. Response CT scans were performed as 
per routine institutional practice, generally after every two 
cycles of systemic therapy. Best response was defined at 
time of first response assessment CT. Overall survival was 
measured both from date of initial diagnosis and from date 
of first dose of first-line chemotherapy, until date of death 
or last clinical follow-up. Statistical analysis was calculated 
using Medcalc version 18.
Results
Patient clinicopathological characteristics
A summary of baseline clinicopathological characteristics is 
displayed in Table 1. In total, we identified 13 patients who 
were diagnosed with SEF between 1990 and 2017. SEF was 
found in balanced distribution among both sexes. Median 
age of diagnosis was 44.6 years old (26.5–65.6 years) with 
3/13 (23.1%) patients diagnosed below the age of 35 years.
The most common primary tumour sites were the lower 
limbs (7/13, 53.8%) followed by the chest (5/13, 38.5%) and 
the neck (1/13, 7.7%). Grade and maximal dimension of pri-
mary tumour were available for 11/13 and 10/13 patients, 
respectively—7/11(64%) grade 1, 1/11 (9%) grade 2 and 
3/11 (23%) grade 3. Median primary tumour size was 9 cm 
(range 3–25 cm).
Eleven out of 13 (84.6%) patients had localised disease 
at first presentation, all of whom underwent treatment with 
radical intent. Local recurrence occurred in all 11 patients 
and ultimately 10/11 (90.9%) patients developed metachro-
nous metastatic disease. In patients that developed metachro-
nous metastatic disease, median metastasis-free interval 
following diagnosis was 12.4 months (95% CI 5.3–20.6). 
Two out of 13 (16.7%) patients presented with synchronous 
metastatic disease. The most common metastatic sites were 
lung (8/12, 66.7%) and bone (6/12, 50%), other metastatic 
sites included the liver, brain and abdomen seen in 1 patient 
each. At the point of data cut-off, 10/13 patients had died 
of metastatic disease, one patient had recently commenced 
palliative chemotherapy for metastatic disease, one patient 
with metastatic SEF was lost to follow-up after 21.6 months 
post-diagnosis and one patient remained disease-free after 
nearly 9 years of follow-up after a second radical resection 
of locally recurrent SEF originating from the thigh.
Surgical and radiological management of disease
Oncological management of all 13 patients is summarised in 
Table 1. In all 11 patients who underwent radical resection 
for localised disease, microscopic involvement of resection 
margins (R1) was reported. Three out of 11 patients, all of 
whom had large (> 10 cm), proximally located tumours, 
received post-operative radiotherapy to the surgical bed, 
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with a total dose of 68 Gy or 50 Gy delivered in 2/3 and 1/3 
patients, respectively. All radically treated patients experi-
enced tumour relapse. Seven out of 11 had metastatic disease 
at first relapse. Four out of 11 initially had local recurrence 
only, with resection of recurrence attempted in all 4 patients. 
Three out of 4 patients ultimately relapsed with metastatic 
disease while only 1 patient had no evidence of disease with 
a follow-up of 105 months from initial diagnosis—notably, 
this was the only patient where R0 resection was achieved. 
Patients 4, 5, 6 and 7 underwent metastectomy to remove 
SEF metastases to the lungs and lymph nodes.
Systemic chemotherapy in SEF
Among the 12 patients with metastatic SEF, 7 patients 
received at least one line of systemic chemotherapy, 2 
patients were unfit for chemotherapy and received best sup-
portive care, 1 patient declined chemotherapy, 1 patient 
with bone-only metastases received zoledronic acid and 1 
patient was lost on follow-up due to transfer of care. Table 1 
outlines 1st line systemic chemotherapy administered to 7 
patients with metastatic SEF and associated outcomes. All 
patients had radiologically progressive disease prior to com-
mencement of chemotherapy. Three patients were treated 
with single agent doxorubicin and received a median of 4 
(range 2–6) cycles. Three patients were treated with com-
bination doxorubicin and ifosfamide, receiving between 
5 and 6 cycles. One patient was treated with 2 cycles of 
combination gemcitabine and docetaxel. One patient had a 
partial response to doxorubicin/ifosfamide chemotherapy, 3 
had stable disease (all with doxorubicin monotherapy) and 
3 had progressive disease.
Only patient 5 had additional lines of chemotherapy; fol-
lowing progression after 2 cycles of 1st line gemcitabine/
docetaxel, this consisted of 6 cycles of oral cyclophospha-
mide and 3 cycles of trabectedin for 2nd and 3rd line, respec-
tively. Best response with cyclophosphamide was stable 
disease with an associated progression-free survival of 9.9 
months while progressive disease was seen after 2 cycles of 
trabectedin.
Survival analysis
As illustrated by Fig. 1a–d and Table 1, median overall sur-
vival from diagnosis was 47.3 months (95% CI 25.0–131.9). 
Metastatic-free survival in patients initially diagnosed with 
primary disease was 16.3 months (95% CI 5.3–20.6). In 
patients that received chemotherapy, median progression-
free survival post 1st line chemotherapy (Fig.  1b) was 
2.7 months (95% CI 1.2–4.4). SEF that were intermediate/
high grade at diagnosis had a non-significant trend to lower 
overall survival (HR 3.01, 95% CI 0.46–19.52, p = 0.084) 
and metastases-free survival (HR 2.93, 95% CI 0.59–14.46, 
p = 0.057). Primary tumour size and age of diagnosis were 
not significant predictors of overall and/or metastases-free 
survival.
Discussion
Due largely to its rarity and having only relatively recently 
being recognised as a distinct diagnostic entity, SEF is asso-
ciated with a limited published literature. Consequently, 
there are few published studies describing the clinical phe-
notype, molecular biology and optimal management of this 
cancer. We have reported the largest case series of SEF 
with annotated follow-up of treatment outcomes and have 
identified important features that should inform future man-
agement of a rare STS subtype that is associated with poor 
clinical outcomes.
In our series of 13 patients with confirmed SEF, a major-
ity of patients initially presented with a primary tumour in 
the absence of demonstrable metastatic disease. The clinical 
epidemiology of SEF seen in our cohort is consistent with 
past reports by Meis-Kindblom et al. and Antonescu et al. 
[1, 7]. Specifically, SEF are capable of presenting in patients 
below 35 years old without gender preponderance and pri-
mary tumours were most commonly originating in the lower 
limbs or trunk. Additionally, while histologically primary 
SEF usually appear low grade, they exhibit a high risk of 
metastasis, typically to the lungs and bones. A possible 
explanation behind the cause of this apparent discrepancy 
between low tumour grade and metastatic potential, is the 
progression of malignancy in microscopic locally residual 
SEF. Kanno et al. described a case of SEF with local multi-
ple recurrences over 12 years with eventual bone metastasis 
that had increased Ki67 expression over prior recurrence 
and the original primary tumour. Notably, the sole long-term 
survivor in our cohort was the only patient that achieved 
a R0 resection, re-emphasising the metastatic potential of 
microscopic locally residual SEF.
Anatomical site of primary tumour varied widely between 
individual patients and included proximal and distal extremi-
ties, trunk, head and neck and intra-cavity areas. Seven out 
of 13 patients had tumours with low histological grade yet 
did not demonstrate a significantly less aggressive clinical 
course compared to intermediate or high-grade tumours. 
While eventual progression to metastatic disease seems 
likely, our results suggest that low-grade tumours develop at 
a slower rate relative to intermediate or high-grade tumours.
Despite management in a specialist STS centre, micro-
scopic involvement of surgical margins following radical 
resection was ubiquitous. This suggests a locally infiltra-
tive disease process that may not be adequately captured by 
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macroscopic or radiological assessment of tumour extent 
before or at the time of surgery. This should inform con-
siderations of surgical approach and the use of pre- or post-
operative radiotherapy in pursuit of optimal local disease 
control.
Among the 12 patients, only 3 received adjuvant radio-
therapy, 2 of whom later experienced local recurrence, and 
all three developing metastases. Given the high rates of R1 
resection and local recurrence, and an apparent mismatch 
between histological grade and clinical phenotype, indica-
tion for delivery of adjuvant radiotherapy in SEF may extend 
beyond general recommendations for STS.
In our series, 7 patients received at least one line of 
systemic therapy for advanced disease. Objective tumour 
response was seen in a single patient with a histologically 
high-grade tumour, but was associated with short duration 
of response. Disease stabilisation was seen in three patients 
treated with doxorubicin, with radiological disease control 
lasting 1.2, 2.7 and 7 months, respectively. Progressive dis-
ease was seen in the other patients after an assortment of 
regimens commonly used in the treatment of advanced STS. 
These findings suggest that SEF has a chemo-sensitivity 
in keeping with a large proportion of other STS subtypes, 
where occasional tumour sensitivity is demonstrated in the 
context of likely limited benefit delivered to a majority of 
patients. In terms of overall systemic chemotherapy response 
to SEF, similar median progression-free survival and overall 
survival were observed in systemic chemotherapy for other 
types of metastatic soft tissue sarcoma [8]. While, at present, 
it appears reasonable to continue to offer available regimens 
for advanced SEF, this must be done with anticipation of 
benefitting a minority of patients. Meanwhile, more effec-
tive and well-tolerated systemic therapies are in acute need. 
Thus, clinicians should consider offering patients participa-
tion in clinical trials [9]. Additionally, further investigation 
into potential therapeutic targets may provide more effective 
treatments. Arbajian et al. recently characterised a series of 
SEF and low-grade fibromyxoid sarcoma and compared gene 
expression against those expressed by fibroblast cells trans-
fected with EWSR1-CREB3L1. They reported that additional 
genetic mutations may explain the differences in malignant 
potential between the two tumours. Specifically, SEF had 
Fig. 1  Kaplan–Meier curves for overall survival from diagnosis (a), progression-free survival from 1st line chemotherapy (b), overall survival 
from diagnosis based on primary tumour grade (c) and metastatic free survival based on primary tumour grade (d)
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recurrent DMD microdeletions and upregulation of CD24 
and provided a possible lead for therapeutic targets [10].
Patients that were metastatic at diagnosis tended to be 
those with large deep-seated tumours located centrally [11]. 
The asymptomatic nature of SEF coupled with the large pri-
mary tumour size suggested a long-standing malignancy and 
is in keeping with the possibility of SEF slowly developing 
the ability to metastasize overtime in these patients.
While SEF had an extremely high potential to metasta-
size, there is a marked heterogeneity in the aggressiveness 
of the tumour. Nearly half of our patients reached the 3-year 
survival mark with some surviving for more than 10 years 
while conversely a third passed away within the first year. 
Additionally, even when metastasis has occurred, a handful 
of patients continue to be clinically well for a number of 
years before having to start systemic chemotherapy. This 
heterogeneity in the clinical phenotype of SEF may, in part, 
be related to variation in underlying molecular pathology. 
Doyle et al. [3] described two different subsets of SEF. 
Firstly, a MUC4-positive SEF that lack FUS rearrangement 
which may be related to the less malignant low-grade fibro-
myxoid sarcoma. Secondly, a SEF lacking MUC4 expres-
sion that could be a more aggressive form of SEF as MUC4 
expression had been reported to be associated with epithelial 
glandular differentiation in other sarcomas. The ability to 
better identify and segregate the different subsets of SEF 
through immunohistochemistry or cytogenetics would aid 
clinicians to better weigh the balance between benefit and 
toxicity of systemic chemotherapy.
Conclusion
In summary, in our series of patients treated at a specialist 
sarcoma centre, SEF is a clinically heterogeneous disease 
with an apparent locally and systemically infiltrative phe-
notype that translates to a high rate of local and metastatic 
recurrence. Prolonged survival may be attained in patients 
who can be rendered free of macroscopic disease following 
recurrence. Sensitivity to chemotherapy regimens widely 
used for STS appears to be limited. There is an urgent need 
for the improvement of outcomes following management of 
localised and advanced disease. Optimisation of currently 
available surgical, radiation and drug modalities should be 
pursued through international collaboration. Further under-
standing of underlying disease biology should be sought in 
the hope of identifying novel therapeutic vulnerabilities. As 
SEF is an extremely rare cancer even among sarcomas, the 
only feasible way of collecting a sizable patient cohort to 
review treatment outcomes is via collaborations with other 
international specialised sarcoma clinics.
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